Rappi and dLocal Further Expand Their Partnership and Add PIX Brazil’s Payment Method
dLocal, the leading payment platform connecting global merchants to emerging markets, today announced its expanded partnership with Rappi, an on-demand delivery startup operating in Latin America. Under the strengthened alliance, Rappi’s customers in Brazil can now opt to use PIX payments for purchases made in the Rappi app.
PIX adoption growth rate has been among those instant payment systems with the fastest adoption around the world. A year after roll out, Brazil's instant payment system represents 72% of the country’s transactions. The Central Bank of Brazil disclosed that over 100 million people have already executed at least one PIX transaction since it’s roll out in November 2019.
Rappi customers in Brazil will now have the ability through dLocal’s payments platform to make purchases with local credit card payments – including Mastercard, Visa, and American Express cards issued by local banks – at the moment the service is available for ordering in restaurants, e-commerce and cash, and in the next 6 months it will be available across all the app. This is the first time Rappi will be using this highly accepted alternative payment method, such as PIX.
The payments infrastructure in Brazil and other emerging markets in Latin America, Asia and Africa is fragmented and complex. By adding the ability to accept locally relevant payment methods, Rappi will continue to improve the lives of millions in the region, creating a seamless payment experience in the first super-app for Latin America.
“dLocal has been a trusted partner for our operation in Latin America over the last couple of years. By offering one of the latest payment innovations in Brazil, such as PIX, we are taking the next step in our partnership to further improve our customer experience and offer localized payment methods focused on the consumer preferences and habits,” said Carlos Ayalde, Global Heads of Payments in Rappi.
“We are proud to have Rappi as a customer, to provide our local expertise to their consumers and provide a seamless checkout experience by offering them multiple local and alternative payments methods,” said Michel Golffed, VP Growth, dLocal.
Rappi partners with dLocal in order to leverage their tailored made payment solutions focused in gig-economy companies. dLocal offers payins, in order to users to buy products in rappi, payouts, process payouts to restaurants and couriers and also, issue white label cards for rappi's aliados.
Rappi and dLocal have committed to offering localized payments in Argentina, Brazil, Chile, Costa Rica, Mexico, and Uruguay, with the intention of expanding the partnership between Rappi and dLocal to other countries, offering more relevant methods of payments.
About dLocal
dLocal powers local payments in emerging markets connecting global enterprise merchants with billions of emerging market consumers across Africa, Asia, Latin America, and the Middle East. Through the “One dLocal” concept (one API, one platform, one contract), global companies can accept payments, send pay-outs, settle funds globally, and issue white label prepaid virtual and physical debit cards in local currencies, without the need to manage separate pay-in and payout processors, set up numerous local entities, and integrate multiple acquirers and payment methods in each market. Learn more at https://dlocal.com.
About Rappi
Rappi is an all-purpose delivery application that aims to be the personal assistant for its users. The LatAm-based startup is present in Brazil, Colombia, Mexico, Argentina, Chile, Uruguay and Peru. Through the platform, it is possible to buy products of different categories, from Restaurants, Supermarkets and Beverages to literally anything. In addition, the application has a virtual wallet, RappiPay, where it is possible to make transfers and even payments in establishments. In 2016, the company was accelerated by Y Combinator, the most important incubator of startups in the world. At the beginning of 2018, it received a contribution of US $185 million, which allowed its expansion in Brazil and Latin America; in September of 2018, it received a new contribution, this time US $220 million, becoming the new Latin American unicorn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005025/en/
Contact information
Marta Seitz
dlocal@backbaycommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom